NZ726348A - Androgen receptor modulators and methods for their use - Google Patents

Androgen receptor modulators and methods for their use

Info

Publication number
NZ726348A
NZ726348A NZ726348A NZ72634815A NZ726348A NZ 726348 A NZ726348 A NZ 726348A NZ 726348 A NZ726348 A NZ 726348A NZ 72634815 A NZ72634815 A NZ 72634815A NZ 726348 A NZ726348 A NZ 726348A
Authority
NZ
New Zealand
Prior art keywords
compound
cancer
acid
compounds
alkyl
Prior art date
Application number
NZ726348A
Other languages
English (en)
Inventor
Nasrin R Mawji
Raymond J Andersen
Luping Yan
Marianne Sadar
Carmen Banuelos
Original Assignee
Univ British Columbia
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, British Columbia Cancer Agency Branch filed Critical Univ British Columbia
Publication of NZ726348A publication Critical patent/NZ726348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ726348A 2014-05-30 2015-05-29 Androgen receptor modulators and methods for their use NZ726348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005714P 2014-05-30 2014-05-30
PCT/US2015/033385 WO2015184393A1 (en) 2014-05-30 2015-05-29 Androgen receptor modulators and methods for their use

Publications (1)

Publication Number Publication Date
NZ726348A true NZ726348A (en) 2022-09-30

Family

ID=53373659

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ726348A NZ726348A (en) 2014-05-30 2015-05-29 Androgen receptor modulators and methods for their use

Country Status (8)

Country Link
US (2) US9682933B2 (enExample)
EP (1) EP3148970B1 (enExample)
JP (3) JP2017516862A (enExample)
AU (3) AU2015266654A1 (enExample)
CA (1) CA2948643C (enExample)
IL (1) IL249203B (enExample)
NZ (1) NZ726348A (enExample)
WO (1) WO2015184393A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339300B (es) 2008-08-22 2016-05-19 British Columbia Cancer Agency Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
JP2017516862A (ja) * 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
SG11202007873VA (en) * 2018-03-05 2020-09-29 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
WO2021021629A1 (en) * 2019-07-26 2021-02-04 University Of Florida Research Foundation, Incorporated Discovery, total synthesis, and bioactivity of doscadenamides
WO2021044061A1 (en) * 2019-09-05 2021-03-11 Klinikum Rechts Der Isar Der Technischen Universität München Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent
US12133846B2 (en) 2019-10-15 2024-11-05 Wayne State University Electrophilic androgen receptor (AR) antagonists for AR downregulation and ferroptosis induction in cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0317057A (ja) 1989-06-15 1991-01-25 Fujisawa Pharmaceut Co Ltd 新規５員環複素環化合物
AU4494399A (en) 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
MX339300B (es) * 2008-08-22 2016-05-19 British Columbia Cancer Agency Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
AU2011312490B2 (en) * 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
JP2017516862A (ja) 2014-05-30 2017-06-22 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲン受容体調節物質及びその使用方法

Also Published As

Publication number Publication date
JP2017516862A (ja) 2017-06-22
CA2948643A1 (en) 2015-12-03
AU2019257509B2 (en) 2021-05-13
EP3148970A1 (en) 2017-04-05
AU2021215137A1 (en) 2021-09-02
JP2021176908A (ja) 2021-11-11
US9682933B2 (en) 2017-06-20
IL249203A0 (en) 2017-01-31
JP2020143126A (ja) 2020-09-10
EP3148970B1 (en) 2022-03-16
WO2015184393A1 (en) 2015-12-03
US10071962B2 (en) 2018-09-11
US20170283377A1 (en) 2017-10-05
AU2019257509A1 (en) 2019-11-21
AU2015266654A1 (en) 2016-12-01
JP6925481B2 (ja) 2021-08-25
IL249203B (en) 2020-08-31
CA2948643C (en) 2022-09-06
US20150344424A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
AU2014262333B2 (en) Ester derivatives of androgen receptor modulators and methods for their use
AU2019257509B2 (en) Androgen receptor modulators and methods for their use
US9365510B2 (en) Aziridine bisphenol ethers and related compounds and methods for their use
JP6190025B2 (ja) ジグリシドエーテル誘導体治療剤およびその使用方法
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
US20200206155A1 (en) Bisphenol ether derivatives and methods for using the same
EP2521707A1 (en) Bisphenol derivatives and their use as androgen receptor activity modulators
JP2019513795A (ja) ビスフェノール誘導体、及びアンドロゲン受容体活性調節因子としてのそれらの使用
OA18988A (en) Ester derivatives of androgen receptor modulators and methods for their use.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230430

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240430

LAPS Patent lapsed